Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
This is a dose escalation and dose expansion study. In this dose escalation phase, eligible participants will receive increasing dose levels of BGB-B167 (administered intravenously [IV]), either alone, or in combination with tislelizumab (aministered via IV). In the dose expansion phase, eligible participants will either receive BGB-B167 alone (via IV), or in combination with tislelizumab (via IV).